Blood test may spare rectal cancer patients from unnecessary surgery
NCT ID NCT07209215
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 22 times
Summary
This study tests whether a sensitive blood test (ctDNA) can help doctors decide the best treatment for people with early-stage rectal cancer. About 200 adults will be enrolled to see if using the blood test leads to better outcomes, like complete tumor disappearance or longer survival without cancer returning. The goal is to personalize care and possibly avoid surgery for some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.